Featured Press Releases

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

Anixa Biosciences has unveiled its Phase 2 study plan for a breast cancer vaccine.

CollPlant expands its partnership with Stemcell Technologies.

CollPlant expands its partnership with Stemcell Technologies.

  • 10 Jun 2025

CollPlant Biotechnologies a regenerative and aesthetics medicine company developing innovative...

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Zafrens expands its investor syndicate to scale its revolutionary drug discovery platform

Upsher-Smith Enhances Generics Portfolio by Introducing Difluprednate Ophthalmic Emulsion

Upsher-Smith Enhances Generics Portfolio by Introducing Difluprednate Ophthalmic Emulsion

Successfully deployed in Myanmar conflict zone, the SurgiField system enables life-saving surgery

Successfully deployed in Myanmar conflict zone, the SurgiField system enables life-saving surgery

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

TIME names Sprout Pharmaceuticals, the maker of Addyi (flibanserin), among the 10 most influential health and life science companies of 2026

  • Sprout Pharmaceuticals
  • 30 Apr 2026
Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

Pharmacists gain a flexible, space-saving option as YARAL Pharma launches its 15-count Diclofenac Epolamine Topical System 1.3%

  • YARAL Pharma Inc.
  • 30 Apr 2026
Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

Lasix® ONYU® Receives CE Marking, Advancing Toward International Authorization; EMA Approves for Centralized Review Based on Innovation

  • SQ Innovation
  • 29 Apr 2026
Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

Rapid Nexus Secures VA and DoD Contracts, Launches Commercial Deployment of FDA-Cleared Wound Technology

  • Rapid Nexus
  • 29 Apr 2026
Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

  • Apertura Gene Therapy
  • 28 Apr 2026
AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

  • AbbVie
  • 28 Apr 2026
The Digital Pharma Advances Conference 2026

Most Popular
May   2026
M T W T F S S
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.